Lawrence M. Blatt, Ph.D. 13D and 13G filings for Aligos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-11-06 4:05 pm Purchase |
2023-10-25 | 13D | Aligos Therapeutics, Inc. ALGS |
Lawrence M. Blatt, Ph.D. | 155,530 5.300% |
48,411 (+45.19%) |
Filing |
| 2023-02-08 4:58 pm Purchase |
2022-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
Lawrence M. Blatt, Ph.D. | 107,119 6.500% |
6,744 (+6.72%) |
Filing |
| 2022-02-10 4:15 pm Purchase |
2021-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
Lawrence M. Blatt, Ph.D. | 100,375 6.200% |
4,500 (+4.69%) |
Filing |
| 2021-02-11 4:18 pm Purchase |
2020-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
Lawrence M. Blatt, Ph.D. | 95,875 6.700% |
95,875 (New Position) |
Filing |